Biodexa CEO reports stock option holdings

Biodexa Pharmaceuticals Plc Chief Executive Officer Stephen Anthony Stamp filed an initial Form 3 reporting his beneficial ownership of stock options.

Rhea-AI Filing Summary

Biodexa Pharmaceuticals Plc Chief Executive Officer Stephen Anthony Stamp filed an initial Form 3 reporting his beneficial ownership of stock options. He holds options to buy 859 American Depositary Shares at an exercise price of $327.5000 per ADS expiring in 2034, and options over 1,500, 25,000 and 15,000 Ordinary Shares at exercise prices of $28.0500, $7.4100 and $5.4000 per share, with expirations between 2029 and 2031. The filing lists existing option awards and does not show any new purchases or sales.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Stamp Stephen Anthony

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 42,359 contracts (Direct)

Footnotes (7)

1. F1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
2. F2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.
3. F3. The shares underlying this option are 100% vested and can be exercised immediately.
4. F4. The exercise price for this option is denominated in British pounds sterling at a price of GBP 259.324 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2629. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
5. F5. The exercise price for this option is denominated in British pounds sterling at a price of GBP 21.00 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
6. F6. The exercise price for this option is denominated in British pounds sterling at a price of GBP 5.55 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
7. F7. The exercise price for this option is denominated in British pounds sterling at a price of GBP 4.04 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Biodexa (BDRX) CEO Stephen Stamp report in this Form 3?

Stephen Anthony Stamp reports his beneficial ownership of several stock option awards. The filing lists options over American Depositary Shares and Ordinary Shares with specified exercise prices and expiration dates, providing a baseline view of his equity-linked compensation position at Biodexa Pharmaceuticals.

Does the Biodexa (BDRX) Form 3 show any stock purchases or sales?

The Form 3 does not show any stock purchases or sales by Stephen Anthony Stamp. It records holdings of stock options as of the reporting date, with transaction codes and summaries indicating no buy or sell activity and only holding entries for derivative securities.

What stock options on American Depositary Shares does the Biodexa CEO hold?

Stephen Anthony Stamp holds a stock option linked to 859 American Depositary Shares. The option has an exercise price of $327.5000 per ADS and an expiration date in 2034, establishing a long-dated equity incentive tied to the company’s ADS structure.

What Ordinary Share options are disclosed for Biodexa (BDRX) in this Form 3?

The Form 3 lists stock options over 1,500, 25,000 and 15,000 Ordinary Shares. These options have exercise prices of $28.0500, $7.4100 and $5.4000 per share, expiring between 2029 and 2031, outlining multiple ordinary-share-based incentive grants.

How are foreign currency exercise prices handled in the Biodexa CEO’s options?

Several option exercise prices are denominated in British pounds sterling, then converted to U.S. dollars for reporting. Footnotes explain the specific GBP prices and the exchange rates used, noting that the actual exercise obligation remains in sterling regardless of later currency movements.

Are any of Biodexa CEO Stephen Stamp’s options already vested according to the filing?

Footnotes describe vesting terms, including a four-year vesting schedule for one option grant and a note that the shares underlying another option are 100% vested. This indicates that at least one option award is fully exercisable as of the dates described in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:30 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stamp Stephen Anthony

(Last) (First) (Middle)

C/O BIODEXA PHARMACEUTICALS PLC

1 CASPIAN POINT, CASPIAN WAY

(Street)

CARDIFF CF104DQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Biodexa Pharmaceuticals Plc [ BDRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/10/2034	American Depositary Shares(2)	859	$327.5(4)	D
Stock Option (right to buy)	(3)	10/02/2029	Ordinary Shares	1,500	$28.05(5)	D
Stock Option (right to buy)	(3)	07/14/2031	Ordinary Shares	25,000	$7.41(6)	D
Stock Option (right to buy)	(3)	06/16/2030	Ordinary Shares	15,000	$5.4(7)	D

Explanation of Responses:

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

3. The shares underlying this option are 100% vested and can be exercised immediately.

4. The exercise price for this option is denominated in British pounds sterling at a price of GBP 259.324 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2629. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

5. The exercise price for this option is denominated in British pounds sterling at a price of GBP 21.00 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

6. The exercise price for this option is denominated in British pounds sterling at a price of GBP 5.55 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

7. The exercise price for this option is denominated in British pounds sterling at a price of GBP 4.04 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney

	/s/ Fiona Mary Powell, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)